Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has been given a consensus rating of “Moderate Buy” by the five brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $16.67.

ATRA has been the topic of a number of analyst reports. Canaccord Genuity Group increased their price objective on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st.

Institutional Trading of Atara Biotherapeutics

Several institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Atara Biotherapeutics during the 2nd quarter worth about $53,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Atara Biotherapeutics in the second quarter worth $79,000. State Street Corp raised its stake in shares of Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 7,680 shares during the period. FMR LLC lifted its holdings in shares of Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 7,381 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 4,043 shares in the last quarter. 70.90% of the stock is owned by hedge funds and other institutional investors.

Atara Biotherapeutics Stock Performance

Atara Biotherapeutics stock opened at $10.35 on Friday. The firm has a market capitalization of $59.62 million, a price-to-earnings ratio of -0.40 and a beta of 0.55. Atara Biotherapeutics has a fifty-two week low of $6.50 and a fifty-two week high of $39.50. The stock’s fifty day moving average is $10.60 and its two-hundred day moving average is $9.65.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.77) by $0.84. The business had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same period last year, the company earned ($16.50) EPS. As a group, sell-side analysts forecast that Atara Biotherapeutics will post -12.12 EPS for the current fiscal year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.